Novel Molecular Descriptors for ADME Prediction in Beyond Rule of Five Chemical Space

Novel Molecular Descriptors for ADME Prediction in Beyond Rule of Five Chemical Space

Publication: Molecular Pharmaceutics
Software: ADMET Predictor®

Beyond Rule of Five (bRo5) molecules, including proteolysis-targeting chimeras (PROTACs), macrocycles, and cyclic peptides, present challenges for conventional ADME prediction because their size, flexibility, polarity, and potential for intramolecular hydrogen bonding (IMHB) can influence solubility, membrane permeability, and downstream pharmacokinetics (PK).

Using Many In Vitro Assay Systems to Make a Kidney Toxicity Prediction of Doxorubicin: A Proof of Concept in Support of the New Approach Methodologies Initiative

Using Many In Vitro Assay Systems to Make a Kidney Toxicity Prediction of Doxorubicin: A Proof of Concept in Support of the New Approach Methodologies Initiative

Conference: ACoP
Software: RENAsym®

With the introduction of the new approach methodologies (NAMs) initiative, there is a focus on finding alternatives to animal studies to validate a drug’s safety before administering in humans.

Complementing QSP with Machine Learning to Predict IGA-Based Population Response in an Atopic Dermatitis Model

Complementing QSP with Machine Learning to Predict IGA-Based Population Response in an Atopic Dermatitis Model

Conference: ACoP

Atopic Dermatitis (AD) is a chronic skin condition characterized by inflammation, itching, and redness. AD is an active area of drug development, with 120+ drug candidates in various stages of pre-clinical and clinical development[1].

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use

Simulations Plus Announces Completion of Acquisition by Altaris

Simulations Plus Announces Completion of Acquisition by Altaris

The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.